Valuation: Tectonic Therapeutic, Inc.

Market Cap 403M 362M 331M 302M 569M 37.93B 587M 3.99B 1.59B 20.24B 1.51B 1.48B 63.89B P/E 2026 *
-4.12x
P/E 2027 * -3.94x
Enterprise Value 78.57M 70.47M 64.4M 58.79M 111M 7.39B 114M 776M 310M 3.94B 295M 289M 12.44B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
62.35%
Yield 2026 *
-
Yield 2027 * -
1 day+6.28%
1 week+4.35%
Current month+4.35%
1 month-9.11%
3 months-33.38%
6 months-23.19%
Current year-1.05%
1 week 18.54
Extreme 18.535
20.89
1 month 18.54
Extreme 18.535
23.61
Current year 16.77
Extreme 16.77
39.53
1 year 16.77
Extreme 16.77
39.53
3 years 13.7
Extreme 13.7
61.07
5 years 13.7
Extreme 13.7
61.07
10 years 13.7
Extreme 13.7
61.07
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Sell

Chief Technology Officer

-536 0.0027%
9/25/26 A Tax

Chief Technology Officer

-525 0.0027%
9/25/26 A Tax

Chief Executive Officer

-1,545 0.0079%
Change 5-day change 1-year change 3-year change Capi.($)
+6.28%+4.35%+6.83% - 403M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.64%+2.82%+44.95%+185.99% 40.71B
Weighted average by Cap. +0.66%+3.07%+49.86%+165.88%

Financials

2026 *2027 *
Net sales - -
Net income -103M -92.06M -84.13M -76.8M -145M -9.65B -149M -1.01B -404M -5.15B -385M -377M -16.25B -135M -121M -110M -101M -190M -12.65B -196M -1.33B -530M -6.75B -505M -494M -21.31B
Net Debt -325M -291M -266M -243M -458M -30.54B -473M -3.21B -1.28B -16.3B -1.22B -1.19B -51.45B -321M -288M -263M -240M -453M -30.19B -467M -3.17B -1.27B -16.11B -1.21B -1.18B -50.86B
Projected Income Statement - Annual - Tectonic Therapeutic, Inc.
Logo Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.
Employees
60
Date Price Change Volume
06/11/26 $20.64 +6.28% 310,817
05/11/26 $19.42 -4.33% 109,568
04/11/26 $20.30 +6.95% 221,544
03/11/26 $18.98 0.00% 198,953
02/11/26 $18.98 -4.04% 183,873
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Tectonic Therapeutic, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.64USD
Average target price
71.00USD
Spread / Average Target
+243.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tectonic Therapeutic, Inc.
  1. Stock Market
  2. Stocks
  3. TECX Stock